102 related articles for article (PubMed ID: 23570400)
1. The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.
Foged NT; Brügmann A; Jørgensen JT
Expert Rev Mol Diagn; 2013 Apr; 13(3):233-42. PubMed ID: 23570400
[TBL] [Abstract][Full Text] [Related]
2. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
3. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
4. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
5. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
[TBL] [Abstract][Full Text] [Related]
6. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
9. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
11. Should HER2 status be routinely measured for all breast cancer patients?
Ravdin PM
Semin Oncol; 1999 Aug; 26(4 Suppl 12):117-23. PubMed ID: 10482203
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
[No Abstract] [Full Text] [Related]
13. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
[TBL] [Abstract][Full Text] [Related]
14. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.
Cayre A; Mishellany F; Lagarde N; Penault-Llorca F
Breast Cancer Res; 2007; 9(5):R64. PubMed ID: 17908324
[TBL] [Abstract][Full Text] [Related]
16. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
[TBL] [Abstract][Full Text] [Related]
17. Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT
Pathol Res Pract; 2016 Aug; 212(8):735-42. PubMed ID: 27461826
[TBL] [Abstract][Full Text] [Related]
18. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
20. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
